To include your compound in the COVID-19 Resource Center, submit it here.

ABT-450 plus ritonavir/ombitasvir: Additional Phase III data

Additional data from the open-label, international Phase III TURQUOISE-II (Study M13-099) trial in 380 patients with chronic HCV genotype 1 infection with compensated liver cirrhosis showed that AbbVie's all-oral 3D regimen - comprising co-administration with once-daily 150 mg ABT-450 plus 100 mg ritonavir, once-daily 25 mg ABT-267 and twice-daily 250 mg ABT-333 - with ribavirin for 12 weeks led to an SVR

Read the full 623 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE